Elemental impurities remain a critical consideration in pharmaceutical quality systems because trace metal contaminants can affect product safety, regulatory compliance, and overall product quality. To manage these risks, pharmaceutical manufacturers are expected to follow the principles outlined in ICH Q3D, which provides a risk-based framework for evaluating and controlling elemental impurities.

However, one of the most common questions during product development and quality assessment is:

Is an elemental impurity risk assessment sufficient, or is confirmatory ICP-MS testing also required?

The answer depends on product-specific risk factors, available scientific justification, manufacturing processes, and regulatory expectations.

While risk assessments help identify potential sources of elemental contamination, confirmatory analytical testing provides the data needed to verify whether elemental impurities are actually present at levels of concern.

Understanding the difference between these two activities is essential for building an effective elemental impurity control strategy.

When Do You Need Risk Assessment and When Do You Need Confirmatory Testing?

Elemental impurity risk assessment is used to identify and evaluate potential sources of elemental contamination throughout pharmaceutical manufacturing. Confirmatory ICP-MS testing is used to verify whether elemental impurities are present and quantify their concentration. In many situations, risk assessment serves as the first step, while confirmatory testing is performed when potential risks cannot be adequately justified through scientific evaluation alone.

Quick Takeaway

Risk assessment identifies the possibility of elemental impurity contamination. Confirmatory ICP-MS testing determines whether contamination actually exists and whether levels remain within acceptable limits. Together, these approaches help support ICH Q3D compliance and pharmaceutical quality assurance.

When Do You Need Risk Assessment and When Do You Need ICP-MS Testing?

A common misconception is that elemental impurity risk assessment and confirmatory testing are interchangeable. In reality, they serve different purposes and are often used together.

Use Risk Assessment When…	Use ICP-MS Testing When…
Potential contamination sources need to be identified	Actual elemental impurity levels must be measured
Manufacturing processes are well understood	Uncertainty remains after risk assessment
Historical analytical data is available	New suppliers or materials have been introduced
Supplier qualification programs are established	Manufacturing or equipment changes have occurred
A science-based justification is being developed	Regulatory or quality requirements require analytical verification
Initial impurity control strategies are being established	Additional evidence is needed to support decision-making

The most effective elemental impurity control programs typically combine both approaches rather than relying exclusively on one.

Understanding Elemental Impurity Risk Assessment

Elemental impurity risk assessment is a systematic evaluation of potential sources of metal contamination within a pharmaceutical product and its manufacturing process.

The goal is to identify where elemental impurities could originate and determine whether they represent a meaningful risk to product quality or patient safety.

Potential sources may include:

• Active pharmaceutical ingredients (APIs)
• Excipients
• Raw materials
• Water systems
• Manufacturing equipment
• Processing aids
• Container closure systems
• Packaging materials

Risk assessment helps manufacturers prioritize investigation efforts and determine whether further analytical evaluation is required.

Why Risk Assessment Is Required Under ICH Q3D

ICH Q3D promotes a science-based and risk-based approach to elemental impurity control.

Rather than requiring routine testing of every product under all circumstances, the guideline encourages manufacturers to:

• Identify potential elemental impurity sources
• Evaluate contamination risk
• Establish appropriate control strategies
• Generate supporting scientific justification

This approach allows resources to be focused where contamination risks are most likely to occur.

What Is Confirmatory ICP-MS Testing?

Confirmatory testing involves the analytical measurement of elemental impurities within pharmaceutical materials or finished products.

The most widely used technique is:

Inductively Coupled Plasma–Mass Spectrometry (ICP-MS)

ICP-MS offers:

• Trace-level detection capability
• Multi-element analysis
• High sensitivity
• Excellent quantitative performance
• Broad elemental coverage

Because elemental impurities are often present at very low concentrations, ICP-MS has become the preferred analytical technique for pharmaceutical elemental impurity investigations.

Risk Assessment vs Confirmatory Testing: What’s the Difference?

Elemental Impurity Risk Assessment	Confirmatory ICP-MS Testing
Identifies potential contamination sources	Measures actual elemental impurity levels
Based on scientific evaluation	Based on analytical data
Evaluates theoretical risk	Confirms real-world concentrations
Supports control strategy development	Supports compliance verification
Often performed early in development	Often performed when additional evidence is needed
May reduce unnecessary testing	Provides direct quantitative results

Risk assessment and confirmatory testing are complementary rather than competing activities.

When Risk Assessment Alone May Be Sufficient

In some situations, a comprehensive and scientifically justified risk assessment may adequately demonstrate low contamination risk.

Examples may include:

• Well-characterized manufacturing processes
• Low-risk excipient profiles
• Established supplier qualification programs
• Historical analytical data supporting low risk
• Products with minimal elemental impurity exposure potential

In these cases, available scientific evidence may provide sufficient justification without extensive additional testing.

However, decisions should always be supported by appropriate documentation and risk-based reasoning.

When Confirmatory ICP-MS Testing Becomes Important

Confirmatory testing is often recommended when uncertainty remains after risk assessment.

Common situations include:

New Product Development

Limited historical data may require analytical verification.

New Suppliers

Changes in raw material sources may introduce uncertainty.

Process Changes

Manufacturing modifications can affect contamination risk.

Equipment Changes

New equipment may introduce different elemental exposure pathways.

Regulatory Expectations

Analytical data may be needed to support submissions or inspections.

Elevated Risk Profiles

Products with multiple potential contamination sources often benefit from confirmatory testing.

Practical Example: When Documentation Alone Is Not Enough

In practice, confirmatory ICP-MS testing often becomes valuable when supplier changes, equipment updates, or manufacturing modifications introduce uncertainty that cannot be fully resolved through documentation alone.

For example, a manufacturer may qualify a new excipient supplier whose material specifications appear equivalent to those of the previous supplier. While the risk assessment may indicate low elemental impurity risk, confirmatory ICP-MS testing can provide analytical evidence that elemental impurity levels remain within acceptable limits and support continued confidence in the control strategy.

This combination of risk assessment and analytical verification helps strengthen impurity control programs and supports regulatory readiness.

Topiox 4-Question Framework for Elemental Impurity Verification

When determining whether confirmatory testing is required, four practical questions can help guide decision-making:

1. Are Potential Sources of Contamination Clearly Understood?

Evaluate APIs, excipients, water systems, processing aids, equipment, and packaging materials.

2. Is Reliable Historical Data Available?

Previous elemental impurity testing results may strengthen risk-based justifications and reduce uncertainty.

3. Have Significant Changes Occurred?

Supplier changes, manufacturing modifications, equipment upgrades, or formulation changes may increase elemental impurity risk.

4. Would Analytical Verification Improve Confidence?

If uncertainty remains, confirmatory ICP-MS testing can provide direct evidence regarding elemental impurity levels.

This framework supports a balanced approach that combines scientific risk assessment with analytical verification where appropriate.

Example: Risk Assessment Alone vs Risk Assessment Plus Testing

Consider two pharmaceutical products.

Scenario 1: Low-Risk Product

A product uses well-characterized excipients from qualified suppliers, has stable manufacturing processes, and possesses extensive historical impurity data.

A documented risk assessment may provide sufficient justification.

Scenario 2: Higher-Risk Product

A product incorporates new suppliers, modified manufacturing equipment, and recently introduced process changes.

In this case, confirmatory ICP-MS testing may be valuable for verifying that elemental impurity levels remain within acceptable limits.

This comparison illustrates why testing requirements often depend on product-specific circumstances.

Regulatory Expectations for Elemental Impurity Control

Global regulatory authorities increasingly expect manufacturers to implement risk-based impurity control programs.

Effective programs typically include:

• Risk assessment
• Supplier qualification
• Process understanding
• Control strategies
• Analytical verification where appropriate
• Ongoing lifecycle monitoring

These activities support compliance with ICH Q3D principles and broader pharmaceutical quality expectations.

How Topiox Research Centre Supports Elemental Impurity Assessment

At Topiox Research Centre, elemental impurity evaluations combine scientific risk assessment with advanced analytical testing capabilities.

Our support may include:

• Elemental impurity risk assessment
• ICP-MS method development
• Confirmatory elemental impurity testing
• Method validation
• Regulatory-focused reporting
• Supplier qualification support
• Stability-related impurity investigations

By integrating risk-based evaluation with trace-level analytical verification, organizations can establish more robust elemental impurity control strategies.

Learn more about our elemental impurity analysis services and ICP-MS testing capabilities.